mClinical Endocrimolegistsrtyd coto f r rino Am20( -tern 6ioDBanKKatMMh A:Thyroid h -283 currence of hyper se nged useo 010,952123-2131 MF.Anil C 63 Pearce SH:Sp a retro .Glang),Kanitz M.Pitz 6的 H, a l: 98:47 in] 0 66 thyro 0162 0 ang v 560 is hyh 57 Seoch SC.Clark ing and ge tudy Na 20156763 es in 681 6 FW. M.M A: ndtz M. Mag formance rug-ind Lancet aLD r with Hashin 20164 B.Di Blas 69 S,Arts tiaaio hat m nulatin LA.Nete (TSAb)can predict re id d ent.ICn En- aron P:Su in France Eur 2018 ETA Guideline for the Management 183 of Graves'Hyperthyroidism 医肺润 http://guide.medlive.cn/2018 ETA Guideline for the Management of Graves’ Hyperthyroidism Eur Thyroid J 2018;7:167–186 183 DOI: 10.1159/000490384 34 Diana T, Wuster C, Kanitz M, Kahaly GJ: Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies. J Endocrinol Invest 2016;39:1159–1165. 35 Diana T, Wüster C, Olivo PD, Unterrainer A, König J, Kanitz M, Bossowski A, Decallonne B, Kahaly GJ: Performance and specificity of six immunoassays for TSH receptor anti￾bodies: a multicenter study. Eur Thyroid J 2017;6:2. 36 Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ: A novel thyroid stimu￾lating immunoglobulin bioassay is a func￾tional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab 2010;95:2123–2131. 37 Ponto KA, Kanitz M, Olivo PD, Pitz S, Pfeiffer N, Kahaly GJ: Clinical relevance of thyroid￾stimulating immunoglobulins in graves’ ophthalmopathy. Ophthalmology 2011;118: 2279–2285. 38 Ponto KA, Diana T, Binder H, Matheis N, Pitz S, Pfeiffer N, Kahaly GJ: Thyroid-stimulating immunoglobulins indicate the onset of dys￾thyroid optic neuropathy. J Endocrinol Invest 2015;38:769–777. 39 Kahaly GJ, Diana T, Glang J, Kanitz M, Pitz S, Konig J: Thyroid stimulating antibodies are highly prevalent in Hashimoto’s thyroiditis and associated orbitopathy. J Clin Endocrinol Metab 2016;101:1998–2004. 40 Diana T, Brown RS, Bossowski A, Segni M, Niedziela M, Konig J, Bossowska A, Ziora K, Hale A, Smith J, Pitz S, Kanitz M, Kahaly GJ: Clinical relevance of thyroid-stimulating au￾toantibodies in pediatric graves’ disease – a multicenter study. J Clin Endocrinol Metab 2014;99:1648–1655. 41 Kampmann E, Diana T, Kanitz M, Hoppe D, Kahaly GJ: Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid-associated orbi￾topathy: a prospective study. Int J Endocrinol 2015;2015:678194. 42 Stozek K, Bossowski A, Ziora K, Bossowska A, Mrugacz M, Noczynska A, Walczak M, Pet￾riczko E, Pyrzak B, Kucharska A, Szalecki M, Diana T, Kahaly GJ: Functional TSH receptor antibodies in children with autoimmune thy￾roid diseases. Autoimmunity 2018;51:62–68. 43 Kiefer FW, Klebermass-Schrehof K, Steiner M, Worda C, Kasprian G, Diana T, Kahaly GJ, Gessl A: Fetal/neonatal thyrotoxicosis in a newborn from a hypothyroid woman with Hashimoto thyroiditis. J Clin Endocrinol Metab 2017;102:6–9. 44 Mestman JH: Fetal hyperthyroidism resulted from TSI in a mother with Hashimoto’s hypo￾thyroidism. Clin Thyroidol 2017;29:32–34. 45 McKee A, Peyerl F: TSI assay utilization: im￾pact on costs of Graves’ hyperthyroidism di￾agnosis. Am J Manag Care 2012;18:e1–14. 46 Goichot B, Bouee S, Castello-Bridoux C, Caron P: Survey of clinical practice patterns in the management of 992 hyperthyroid patients in France. Eur Thyroid J 2017;6:152–159. 47 Kahaly GJ, Bartalena L, Hegedus L: The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspec￾tive. Thyroid 2011;21:585–591. 48 Hegedus L: Thyroid ultrasound. Endocrinol Metab Clin North Am 2001;30:339–360. 49 Vitti P, Rago T, Mancusi F, Pallini S, Tonac￾chera M, Santini F, Chiovato L, Marcocci C, Pinchera A: Thyroid hypoechogenic pattern at ultrasonography as a tool for predicting re￾currence of hyperthyroidism after medical treatment in patients with Graves’ disease. Acta Endocrinol 1992;126:128–131. 50 Erdogan MF, Anil C, Cesur M, Baskal N, Er￾dogan G: Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism. Thyroid 2007;17:223–228. 51 Ralls PW, Mayekawa DS, Lee KP, Colletti PM, Radin DR, Boswell WD, Halls JM: Color-flow Doppler sonography in Graves disease: “thy￾roid inferno.” AJR Am J Roentgenol 1988; 150:781–784. 52 Kim TK, Lee EJ: The value of the mean peak systolic velocity of the superior thyroidal ar￾tery in the differential diagnosis of thyrotoxi￾cosis. Ultrasonography 2015;34:292–296. 53 Emiliano AB, Governale L, Parks M, Cooper DS: Shifts in propylthiouracil and methima￾zole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab 2010;95:2227–2233. 54 Brito JP, Schilz S, Singh Ospina N, Rodriguez￾Gutierrez R, Maraka S, Sangaralingham LR, Montori VM: Antithyroid drugs – the most common treatment for Graves’ disease in the United States: a nationwide population-based study. Thyroid 2016;26:1144–1145. 55 Cooper DS: Antithyroid drugs in the manage￾ment of patients with Graves’ disease: an evi￾dence-based approach to therapeutic contro￾versies. J Clin Endocrinol Metab 2003;88: 3474–3481. 56 Cooper DS: Antithyroid drugs. N Engl J Med 2005;352:905–917. 57 Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS: Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev 2010:CD003420. 58 Leschik JJ, Diana T, Olivo PD, Konig J, Krahn U, Li Y, Kanitz M, Kahaly GJ: Analytical per￾formance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol 2013;139:192–200. 59 Giuliani C, Cerrone D, Harii N, Thornton M, Kohn LD, Dagia NM, Bucci I, Carpentieri M, Di Nenno B, Di Blasio A, Vitti P, Monaco F, Napolitano G: A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves’ patients undergoing antithyroid drug (ATD) treatment. J Clin En￾docrinol Metab 2012;97:E1080–E1087. 60 Laurberg P, Berman DC, Andersen S, Bulow Pedersen I: Sustained control of Graves’ hy￾perthyroidism during long-term low-dose antithyroid drug therapy of patients with se￾vere Graves’ orbitopathy. Thyroid 2011;21: 951–956. 61 Elbers L, Mourits M, Wiersinga W: Outcome of very long-term treatment with antithyroid drugs in Graves’ hyperthyroidism associated with Graves’ orbitopathy. Thyroid 2011;21: 279–283. 62 Leger J, Carel JC: Management of endocrine disease: arguments for the prolonged use of antithyroid drugs in children with Graves’ disease. Eur J Endocrinol 2017;177:R59-R67. 63 Pearce SH: Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol 2004;61:589–594. 64 Yang J, Zhu YJ, Zhong JJ, Zhang J, Weng WW, Liu ZF, Xu Q, Dong MJ: Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: a retrospec￾tive analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Thyroid 2016;26:627–633. 65 Nakamura H, Miyauchi A, Miyawaki N, Imagawa J: Analysis of 754 cases of antithy￾roid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab 2013; 98:4776–4783. 66 Watanabe N, Narimatsu H, Noh JY, Yamagu￾chi T, Kobayashi K, Kami M, Kunii Y, Mu￾kasa K, Ito K, Ito K: Antithyroid drug-in￾duced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancyto￾penia involving 50,385 patients with Graves’ disease. J Clin Endocrinol Metab 2012; 97:E49–E53. 67 Chen PL, Shih SR, Wang PW, Lin YC, Chu CC, Lin JH, Chen SC, Chang CC, Huang TS, Tsai KS, Tseng FY, Wang CY, Lu JY, Chiu WY, Chang CC, Chen YH, Chen YT, Fann CS, Yang WS, Chang TC: Genetic determi￾nants of antithyroid drug-induced agranulo￾cytosis by human leukocyte antigen genotyp￾ing and genome-wide association study. Nat Commun 2015;6:7633. 68 Hallberg P, Eriksson N, Ibanez L, Bondon￾Guitton E, Kreutz R, Carvajal A, Lucena MI, Ponce ES, Molokhia M, Martin J, Axelsson T, Yue QY, Magnusson PK, Wadelius M; EuDACc: Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes Endocrinol 2016;4:507–516. 69 Plantinga TS, Arts P, Knarren GH, Mulder AH, Wakelkamp IM, Hermus AR, Joosten LA, Netea MG, Bisschop PH, de Herder WW, Beijers HJ, de Bruin IJ, Gilissen C, Veltman JA, Hoischen A, Smit JW, Netea-Maier RT: Rare NOX3 variants confer susceptibility to agranulocytosis during thyrostatic treatment of Graves’ disease. Clin Pharmacol Ther 2017; 102:1017–1024. http://guide.medlive.cn/